14th Jun 2016 11:06
LONDON (Alliance News) - hVIVO PLC Tuesday confirmed favourable results in a phase IIa study of PrEP-001 in influenza.
PrEP-001 is a nasally administered agent used for the prevention of upper respiratory tract viral infections. Two additional phase IIa studies, a challenge study in asthmatic patients and a dosing study, are currently ongoing.
The company said that full results of the trial will be presented at upcoming scientific conferences and submitted for publication in journals.
"We are delighted to report the Proof of Concept for PrEP-001 in influenza, indicating PrEP-001's potential to have a prophylactic effect across a range of respiratory viruses. With additional phase IIa studies already underway, I look forward to relaying further study results on PrEP-001 in the future," said Chief Executive Kim Denny in a statement.
Shares in hVIVO were down 2.4% at 192.00 pence Tuesday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
hVIVO